Probiotics and autoprobiotics for treatment of Helicobacter pylori infection

Abstract

The article discusses various approaches for probiotic treatment of Helicobacter pylori (H. pylori) infection: Probiotics as an adjuvant treatment in the standard eradication therapy; probiotic strains as a monotherapy; and autoprobiotics as a monotherapy. Autoprobiotics refer to indigenous bifidobacteria, lactobacilli, or enterococci isolated from a specific individual, intended to restore his/her microbiota and improve his/her health. The potential mechanisms of probiotic action against H. pylori include correction of the gut microbiota, immunological effects (enhancement of humoral and cellular immunity, and reduction of oxidative stress), direct antagonistic effects against H. pylori (such as colonization resistance and bacteriocin synthesis), and stimulation of local immunological protection (strengthening of the mucous protective barrier and reduction of gastric mucosa inflammation). The incorporation of probiotics into comprehensive eradication therapy shows promise in optimizing the treatment of H. pylori infection. Probiotics can enhance the eradication rates of H. pylori, reduce the occurrence and severity of side effects, and improve patient compliance. Probiotic or autoprobiotic monotherapy can be considered as an alternative treatment approach in cases of allergic reactions and insufficient effectiveness of antibiotics. We recommend including probiotics as adjunctive medications in anti-H. pylori regimens. However, further randomized multicenter studies are necessary to investigate the effects of probiotics and autoprobiotics against H. pylori, in order to gain a better understanding of their mechanisms of action.

Key Words: Helicobacter pylori; Probiotic; Autoprobiotic; Eradication; Microbiota; Gut; Immunity

Core Tip: The usage of probiotics in complex eradication therapy holds promise for optimizing the treatment of Helicobacter pylori (H. pylori) infection. Probiotics have the potential to enhance the eradication rate of H. pylori, reduce the frequency and severity of side effects, and improve patient compliance. Probiotic and autoprobiotic monotherapies are viable alternatives in cases of allergic reactions or adverse effects caused by antibiotics, owing to their direct antagonistic effect on H. pylori. However, conducting new randomized multicenter studies is necessary to investigate the intricate effects of probiotics and autoprobiotics against H. pylori infection, with the aim of gaining a better understanding of their mechanisms of action.

INTRODUCTION

Helicobacter pylori (H. pylori) infection is one of the most prevalent and extensively studied bacterial infections worldwide. This microorganism serves as a trigger for various conditions, including peptic ulcer disease, chronic gastritis, gastric mucosa-associated lymphatic tissue lymphoma, gastric cancer, and non-gastroenterological issues like iron deficiency anemia. Over the past 35 years, scientists and clinicians in different countries have been striving to identify the most effective regimen for eradicating H. pylori. However, there are several challenges associated with standard eradication regimens, such as antibiotic resistance, low patient compliance due to complex regimens or individual factors, high bacterial density within the stomach, and bacterial internalization. The use of antibiotics in standard H. pylori eradication therapy disrupts the gastrointestinal microbiota, particularly the gut microbiota[1-5]. Therefore, it is crucial to explore H. pylori treatment alternatives that enhance therapy safety and effectiveness while minimizing the negative impact on the gut microbiota. Probiotics represent a potential approach to optimize the management of H. pylori-associated diseases[6,7]. The mention of this treatment method is also found in the Maastricht VI statement, which states that "certain probiotics have demonstrated efficacy in reducing gastrointestinal side effects caused by H. pylori eradication therapies"[8]. However, according to the Toronto consensus, the routine addition of probiotics to eradication therapy to reduce adverse events and improve eradication rates is not recommended due to the very low quality of evidence available[9].

What are probiotics? According to the guidelines of the World Gastroenterology Organization, “probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host”[10]. Medications aimed at correcting the gut microbiota can be categorized into several groups: Real probiotics (containing live microorganisms), metabiotics (containing the byproducts of gut normobiota metabolism), prebiotics (containing substances that serve as nutrients for microorganisms), synbiotics (a combination of probiotics and prebiotics), and symbiotics (a combination of different probiotics). Metabiotics, also known as postbiotics, refer to bacterial metabolites and structural components derived from probiotic microorganisms that have the ability to optimize regulatory, metabolic, and/or behavioral responses associated with the activity of the host organism's native microbiota[11,12]. This article focuses on the use of probiotics and symbiotics (medications containing live microorganisms exclusively) in eradication regimens.

The benefit of the addition of probiotics in anti-H. pylori regimens could restore the alterations of gastrointestinal microbiota induced by antibiotics or proton pomp inhibitors in the regimens. Multiple studies have investigated the effects of probiotics on gastric[13-15], gastrointestinal[16], and gut[17-20] microbiota. Well-known probiotic microorganisms include various species of Bifidobacterium (B. bifidum, B. infantis, B. longum, B. breve, and B. adolescents), Lactobacillus (L. acidophilus, L. plantarum, L. casei, L. bulgaricus, L. lactis, L. reuteri, L. rhamnosus, L. fermentum, L. johnsonii, and L. gassed), non-pathogenic strains of Enterococcus (E. faecium and E. salivarius), certain non-pathogenic species of Escherichia coli, non-pathogenic Bacillus spp. (Bacillus subtilis), lactic acid streptococci (S. thermophilus), yeast fungi such as Saccharomyces boulardii, and newer variants like probiotic products containing Clostridium butyricum or Akkermansia muciniphila[10]. Lactic acid bacteria, particularly Lactobacillus spp., are commonly used as adjunct agents in anti-H. pylori therapy among probiotics[21]. The use of lactobacilli or bifidobacteria as additional medications in eradication therapy is promising because these microorganisms secrete bacteriocins that can inhibit the growth of H. pylori and disrupt its adhesion to the stomach's epithelial cells[22]. Furthermore, the supplemental use of probiotic strains of Bacillus spp. and Enterococcus faecium in triple eradication therapy enhances patient compliance, reduces the frequency and severity of side effects, and increases microbial eradication efficacy[23]. However, the use of these microorganisms may potentiate certain side effects (such as constipation and bloating), and their safety has not been definitively established[24,25]. Therefore, further studies are necessary to investigate their efficacy and safety, particularly for E. faecium, which poses challenges due to antibiotic resistance and potential pathogenicity in certain cases[26].

Medications with probiotic properties not only correct gut microbiota disorders but also offer several additional beneficial effects. These include metabolic benefits, such as a positive impact on metabolic processes and normalization of lipid profiles and blood sugar levels. Furthermore, they contribute to immunological improvements, including enhancements in humoral and cellular immunity and reduction of oxidative stress. Additionally, probiotic medications exert an effect on H. pylori in the stomach through their direct antagonistic action and stimulation of local immune protection, which involves strengthening the protective mucous barrier and reducing the severity of gastric mucosa inflammation[27,28]. Therefore, it is appropriate to consider the overall positive impact of probiotic medications[29,30].

PROBIOTICS ACTION AGAINST H. PYLORI: MYTH OR REALITY?

Probiotics in complex eradication therapy

The efficacy of probiotics in complex eradication therapy has been extensively investigated in numerous scientific studies and analyzed in several meta-analyses.

Several meta-analyses confirm the effectiveness of probiotics as an adjuvant component of eradication therapy in significantly improving the rate of H. pylori eradication and preventing adverse reactions and antibiotic-associated diarrhea[31-33].

In a meta-analysis conducted by Wang et al[34] (2017), which included 140 studies (44 English and 96 Chinese) with 20215 patients, it was found that the eradication rate was 84.1% and the incidence of adverse events was 14.4% in the probiotic group, compared to 70.5% and 30.1%, respectively, in the placebo group. Lactobacillus acidophilus was slightly more effective, while Saccharomyces boulardii was more suitable for 10-d triple therapy.

In another meta-analysis by Feng et al[35] (2017), which included 29 trials (n = 3122), the efficacy of 17 different probiotics was studied. Compared to placebo, probiotic-supplemented triple therapy significantly increased H. pylori eradication rates [relative ratio (RR) = 1.19, 95% confidence interval (CI): 1.13-1.25] and reduced the incidence of total side effects (RR = 0.49, 95%CI: 0.38-0.65). Lactobacillus casei was identified as the most effective for H. pylori eradication (P = 0.84), and a multi-strain combination of Lactobacillus acidophilus and Lactoba-cillus rhamnosus was effective for reducing total side effects (P = 0.93).

According to the data from our prospective open-label study, the additional use of probiotics containing Lactobacillus spp. and Bifidobacterium spp. increases the effectiveness of eradication therapy by 20%-25%[36].

While the effects of probiotics in reducing the frequency of side effects in eradication therapy are widely accepted, the mechanisms by which probiotics increase the effectiveness of treatment are not yet fully understood. It is hypothesized that this may be due to improved compliance resulting from a decrease in the occurrence of side effects, although other mechanisms of probiotic action are also under discussion. The possible mechanisms of probiotic action against H. pylori are illustrated in Figure 1.

Figure 1 Probiotics: Possible mechanisms of action against Helicobacter pylori.

In light of the possible mechanisms of action of probiotics against H. pylori, the question arises: Can we attempt to eradicate H. pylori using probiotics? Research in this area is progressing in two directions.

The first approach involves incorporating probiotics into eradication therapy as an adjuvant treatment. The co-administration of probiotics with anti-H. pylori drugs has been shown to increase the success rate of eradication and reduce the frequency of side effects associated with eradication therapy. Consequently, this approach improves patient compliance with the treatment[37-41]. Another strategy is the administration of probiotics prior to eradication. For instance, the consumption of yogurt containing probiotic strains before starting eradication therapy has demonstrated beneficial effects on the eradication outcome and patient tolerance[42].

The second way studies the effect of probiotic monotherapy in H. pylori eradication. This was recommended to patients who have allergic reactions to antibiotics used in anti-helicobacter therapy regimens and to people who have H. pylori infection without clinical manifestations, for example, H. pylori-positive family members of patients with diseases associated with H. pylori.

METHODOLOGY

For assessment of anti-H. pylori efficacy of adjuvant probiotic treatment, we searched randomized controlled trials about probiotic action against H. pylori in PUBMED for the last 10 years (from 2012 to 2022) with the keywords probiotics and H. pylori. In common there are 438 scientific articles with these key words, of which 56 were clinical trials, 20 were systematic reviews, 23 were meta-analyses, 50 were randomized controlled trials, and 174 were reviews. Of 50 articles with results of randomized controlled trials, 23 estimated the eradication rate of eradication therapy with probiotics/symbiotics treatment with verified probiotic strains. These articles were included in our analysis. For assessment of anti-H. pylori efficacy of probiotic monotherapy, we searched articles about probiotic action against H. pylori in PubMed for the last 10 years (from 2012 to 2022) with the keywords probiotics, monotherapy, and H. pylori. In common there are ten scientific articles with these key words, of which three were clinical trials or randomized controlled trials, two were systematic reviews and meta-analyses, and five were reviews. All of these articles were included in our analysis.

ERADICATION RATE ASSESSMENT OF ERADICATION THERAPY WITH/WITHOUT PROBIOTICS

To review the anti-H. pylori efficacy of adjuvant probiotic treatment, we selected 23 out of the 56 articles that analyzed the eradication rate when probiotics were used in the treatment of H. pylori infection (Tables 1-4). The majority of the articles demonstrated that the addition of probiotics increased the eradication rate. Several papers showed that probiotics did not significantly increase the eradication rate but effectively reduced the side effects of antibiotic therapy. However, one study found that the addition of S. boulardii probiotic to triple antibiotic therapy for H. pylori infection neither increased the eradication rate nor reduced the occurrence of adverse events[43]. These findings highlight the importance of specific strains included in probiotic formulations.

Table 1 Probiotics plus eradication therapy: Assessment of probiotic action against H. pylori: Results for multi-strain probiotics (symbiotics).

Ref.	Patient characteristics	Type of eradication therapy	Type of probiotic	Results
Grgov et al[44], 2016	167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection	7-d triple eradication therapy with lansoprazole continued within 4 wk	Probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755, and Saccharomyces boulardii	(1) Eradication rate in probiotic group-93.3%, in placebo group-81.8% (P < 0.05); and (2) The incidence of adverse effects in probiotic group –17.7%, in placebo group-28.6%
Viazis et al[45], 2022	329 patients in probiotic group and 335 patients in placebo group	10-d proton pump inhibitor containing non-bismuth quadruple therapeutic regimen	The probiotics used combined four probiotic strains, i.e., Lactobacillus Acidophilus, Lactiplantibacillus plantarum, Bifidobacterium lactis, and Saccharomyces boulardii.	(1) Eradication rate in probiotic group-92.0%, in placebo group-86.8% (P = 0.028); and (2) Probiotics significantly decrease side effects
Srinarong et al[46], 2014	100 patients (25 each receiving 7- and 14-d regimens with probiotic or placebo)	7-d and 14-d standard triple therapy plus bismuth	Probiotic bacteria composed of Bifidobacteriumlactis, Lactobacillus acidophilus, and Lactobacillus paracasei	(1) Eradication rates of 7- or 14 d regimens with probiotics were 100%; and (2) The incidence of bitter taste was significantly lower in the probiotic group compared with placebo (40% vs 64%; P = 0.04)
Hauser et al[47], 2015	650 patients	Standard triple eradication therapy	Lactobacillus rhamnosus GG (LGG®) and Bifidobacterium (BB-12®) at a concentration of 108 to 1010 living bacteria	(1) Eradication rate: Probiotics vs placebo-87.38% vs 72.55%; P < 0.001; and (2) Adding probiotics to the standard triple therapy distinctly decreases the adverse effects of therapy
McNicholl et al[48], 2018	209 H. pylori positive patients	33% triple therapy, 66% non-bismuth quadruple therapy	1 × 109 colony-forming units each strain, Lactobacillus plantarum and Pediococcus acidilactici	Probiotic supplementation containing Lactobacillus Plantarum and Pediococcus acidilactici to H. pylori treatment neither decreased side effects nor improved compliance with therapy or eradication rates
Tongtawee et al[49], 2015	200 infected patients	Tailored triple therapy	Pretreatment with probiotics (Lactobacillus delbrueckii and Streptococcus thermophillus) containing yogurt	(1) Eradication rate in probiotic group-90.8%, in placebo group-84.3% (P = 0.04); and (2) Adding probiotics does not reduce adverse effects of the medication
Shavakhi et al[50], 2013	84 patients in the probiotic and 86 in the placebo group	Bismuth-containing quadruple therapy	Probiotic compound contained seven bacterial species including Lactobacillus, Bifidobacterium spp., and Streptococcus thermophiles	(1) Eradication rate in probiotic group-82.1%, in placebo group-81.1% (P = 0.392); and (2) Diarrhea was less frequent (2.2 vs 11.1%, P = 0.016), while abdominal pain was more frequent (10 vs 2.2%, P = 0.029) in the probiotic group
Wang et al[51], 2014	88 H. pylori-infected children: Treatment group (n = 43), control group (n = 45)	Standard triple therapy	Lactobacillus acidophilus and Bifidobacterium bifidum	The eradication rate in probiotic group - 83.7, in placebo group-64.4 % (P < 0.05)
Navarro-Rodriguez et al[52], 2013	107 patients: 55 patients with active probiotics and 52 with placebo	7-d furazolidone, tetracycline, and lansoprazole regimen	Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, and Streptococcus faecium twice a day for 30 d	(1) The eradication rate with probiotics was 89.8% and with placebo, 85.1% (P = 0.49); and (2) The rate of adverse effects at 7 d with probiotics was 59.3% and 71.2% with placebo (P = 0.20)
Tolone et al[53], 2012	68 histopathologically proven H. pylori-infected children	Standard triple therapy	Lactobacillus plantarum 5 × 109, L. reuterii 2 × 109, L. casei subsp. Rhamnosus 2 × 109, Bifidobacterium infantis and B. longum 2 × 109, L. salivarius 109, L. acidophilus 109, Streptococcus termophilus 5 × 109, and L. sporogenes 109	(1) The eradication rate with probiotics was 88.2% and without probiotics 76,4% (P = 0.1); and (2) The addition of a probiotic formula to triple therapy significantly decreased the frequency of epigastric pain, nausea, vomiting, and diarrhea

Table 2 Probiotics plus eradication therapy: Assessment of probiotic action against H. pylori: Results for Bifidobacterium spp. probiotics.

Ref.	Patient characteristics	Type of eradication therapy	Type of probiotic	Results
Çekin et al[54], 2017	159 patients with H. pylori infection	14-d sequential H. pylori eradication therapy	Bifidobacterium animalis subsp. lactis B94 1 capsule/d	(1) Eradication rates in the probiotic group/placebo group were 86.8% vs 70.8%, P = 0.025; (2) Lower first week diarrhea; and (3) Less common self-reported side effects and higher treatment compliance
Dajani et al[55], 2013	377 patients	Standard triple therapy, sequential treatment	Bifidus infantis 2036 at 30 × 108 colony-forming units twice daily	Eradication rate: Standard therapy-68.9%, probiotic with triple therapy- 83%, pre-treatment before triple therapy-90.5%, probiotic with sequential therapy-90.8% (P < 0.05)

Table 3 Probiotics plus eradication therapy: Assessment of probiotic action against H. pylori: Results for Lactobacillus spp. probiotics.

Ref.	Patient characteristics	Type of eradication therapy	Type of probiotic	Results
Poonyam et al[56], 2019	100 subjects were enrolled (72 females, 28 males, mean age = 54 years)	PPI and bismuth-containing quadruple therapy	Lactobacillus reuteri (Biogaia®) in tablets twice daily	(1) Eradication rates with probiotic/placebo were 68%/72% of 7-d regimens and 96%/88% of 14-d regimens; and (2) The incidence of adverse effects was significantly lower in patients in probiotics group
Yang et al[57], 2021	200 treatment-naive H. pylori-positive adult patients	14-d standard triple therapy	Lactobacillus reuteri DSM17648	(1) Eradication rate in the probiotic group - 81.8%, in placebo group-83.7% (P = 0.730); and (2) Probiotic helps improve the microbial profile and reduce the frequency of abdominal distention and diarrhea
Zhu et al[58], 2017	416 children with H. pylori infection	Standard triple therapy, sequential treatment	Lactobacillus	Eradication rate: Sequential group -80.4%, triple group-74%, sequential Lactobacillus group-90.8%, triple Lactobacillus group -88.6%
Francavilla et al[59], 2014	100 H. pylori-positive naive patients	Standard triple therapy	L. reuteri combination (2 × 10 colony-forming units) or placebo during a 3-phase study (pre-eradication, eradication, and follow-up)	(1) Eradication rate was 75% in L. reuteri combination and 65.9% in placebo (P = NS); (2) Significantly less patients in L. reuteri combination as compared with placebo-reported side effects (40.9% vs 62.8%; P < 0.04); and (3) An abnormal gastrin-17 value was found in patients receiving placebo as compared with L. reuteri combination (28% vs 12%; P < 0.02)
Moreno Márquez et al[60], 2022	80 patients	Bismuth-containing quadruple eradication therapy	Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 6475)	(1) Eradication therapy was effective in 85 % of patients, with no differences between treatment arms; and (2) Treatment with L. reuteri only reduced abdominal pain and distension (P < 0.001)
Du et al[61], 2012	234 gastritis patients	Clarithromycin-based triple therapy	Lactobacillus acidophilus 3 × 107	Administration of probiotics before or after standard triple therapy may improve H. pylori eradication rates
Naghibzadeh et al[62], 2022	Quadruple therapy plus L. reuteri (52 patients); Quadruple therapy only (52 patients)	Quadruple therapy: Proton pomp inhibitor, bismuth subcitrate, clarithromycin, and amoxicillin	Lactobacillus reuteri DSMZ 17648	Eradication rate in probiotic group-92.3%, in control group - 86.5%

Table 4 Probiotics plus eradication therapy: Assessment of probiotic action against H. pylori: Results for Saccharomyces boulardii probiotics.

Ref.	Patient characteristics	Type of eradication therapy	Type of probiotic	Results
Seddik et al[63], 2019	199 patients (51.3% males; mean age 44.6 ± 13.6 years)	Standard sequential therapy	Saccharomyces boulardii CNCM I-745	(1) Eradication rate in the probiotic group - 86%, in placebo group – 74.7% (P = 0.02); and (2) Incidence of adverse events in probiotic group - 17%, in placebo group – 55.7% (P < 0.001)
He et al[64], 2019	300 H. pylori-infected patients	Bismuth quadruple therapy	Saccharomyces boulardii	(1) Eradication rate in probiotic group-90.4%, in placebo group-89.0% (P = 0.87); and (2) The overall incidence of adverse reactions and the incidence of diarrhea and nausea in the probiotic group was lower than those in the quadruple group (P < 0.05)
Zhao et al[65], 2014	240 children with a confirmed diagnosis of H. pylori infection	14-d standard triple therapy	Saccharomyces boulardii	(1) The eradication rate was 75.8% in the triple therapy group and 85% in the probiotic group (P > 0.05); and (2) The incidence of stomatitis, constipation, and diarrhea was significantly lower in probiotic group (P < 0.05)
Chang et al[43], 2019	122 patients with infections not resistant to clarithromycin: Triple therapy only (group A, n=61), triple therapy plus probiotics (group B, n = 61)	Clarithromycin-based triple therapy	Saccharomyces boulardii	(1) The eradication rates were similar among the groups both in the intention-to-treat (A = 85.2%, B = 89.6%) and per-protocol (A = 89.2%, B = 86.8%) analyses; and (2) The frequencies of overall adverse events in the groups also did not differ (A vs B: P = 0.574)

According to the information presented in these tables, it is evident that the most commonly used single-strain probiotics are Saccharomyces boulardii and Lactobacillus reuteri strains. As for multi-strain probiotics (symbiotics), the combination of Lactobacillus spp. and Bifidobacterium spp. is widely utilized. Additionally, the inclusion of probiotics in proton pump inhibitor-antibiotics-bismuth regimens has been shown to enhance the safety of anti-H. pylori treatment. Furthermore, due to their multifaceted positive effects, probiotics can contribute to higher eradication rates.

PROBIOTIC MONOTHERAPY

Several studies have confirmed the efficacy of probiotics as monotherapy for H. pylori eradication[27,38,66,67]. For instance, one study reported that a probiotic containing L. acidophilus led to eradication in 6 out of 14 patients[38]. Dore et al[68] (2014) assessed the efficacy of Lactobacillus reuteri (DSM 17938) 108 colony-forming units in combination with pantoprazole 20 mg twice a day for 8 wk in H. pylori eradication. The study defined eradication as a negative result in the ¹³C-urea breath test 4-6 wk after therapy. The results showed that L. reuteri plus pantoprazole achieved eradication in 13.6% of patients by intention-to-treat analysis and 14.2% by per protocol analysis. Another study combining L. reuteri with pantoprazole for 4 wk achieved eradication in 12.5% of patients[69]. Several studies have demonstrated that L. reuteri can inhibit H. pylori growth and decrease bacterial load[59,70,71,72]. This antimicrobial activity may be attributed to the production of compounds such as reuterin, reuteritsin 6, reutetsiklin, and metabolites that inhibit bacterial growth. These compounds can reduce H. pylori adhesion to gastric epithelial cells and inhibit microbial growth, leading to a significant reduction in H. pylori contamination and gastric mucosal inflammation severity[72].

In another study, 40 H. pylori patients were treated with a mixture of eight species of probiotics for 10 d, while 40 H. pylori-positive subjects received a placebo for 1 month. The eradication rate was 32.5% in the probiotic group and 0% in the placebo group[73]. Probiotics containing Lactobacillus acidophilus and Lactobacillus rhamnosus have been shown to reduce the bacterial load of H. pylori according to the ¹³C-urea breath test[17]. The Limosilactobacillus reuteri strain 2892 (L. reuteri 2892) isolated from camel's milk demonstrated the protective effects against H. pylori-induced gastritis in the gastric mucosa in animal models due to significantly downregulated virulence factor cagA gene expression[74]. The combination of fermented milk containing Lactobacillus paracasei and Glycyrrhiza glabra reduced H. pylori density and improved histologic inflammation[75]. Monotherapy with Clostridium butyricum or Bacillus coagulans, and a combination of C. butyricum and B. coagulans showed efficacy for H. pylori eradication in 18%, 20%, and 26% of cases, respectively[76]. However, another study demonstrated no inhibitory activity of a combination of L. acidophilus, L. rhamnosus, and L. sporogenes on H. pylori[77]. S. boulardii monotherapy for 2 wk led to H. pylori eradication in 28.0% of patients based on intent-to-treat criteria[78]. In prospective studies, probiotic monotherapy effectively decreased H. pylori density (based on the ¹³C-urease breath test data) by 2.0% to 64.0%[79]. Initial studies in children have shown promising results for H. pylori eradication with various probiotic strains[80].

Meta-analysis of 11 studies demonstrated that probiotics eradicated H. pylori in 14% of cases (95%CI: 2%-25%, P = 0.02). Specifically, lactobacilli were effective in achieving eradication in 16% (95%CI: 1%-31%), Saccharomyces boulardii in 12% (95%CI: 0%-29%), and multi-strain combinations in 14% (95%CI: 0%-43%). Although probiotic monotherapy had a minimal effect on H. pylori eradication, the successful eradication suggests a possible direct effect of probiotics against H. pylori[81]. A systematic review of 11 high-quality studies concluded that probiotic monotherapy does not significantly affect the eradication rates of H. pylori. However, when used in combination with eradication therapy, probiotics can increase the eradication rates and significantly reduce side effects associated with antibiotics[82].

In an in vitro study conducted by our team, it was observed that the inhibition of H. pylori growth occurred in 50% of cases in contact with a probiotic based on Bacillus subtilis, 78.6% of cases in contact with Enterococcus faecium strain L-3, and 64% of cases in contact with a combination of Bifidobacterium longum and Enterococcus faecium[83]. In an in vivo study, monotherapy with Enterococcus faecium strain L-3 in patients with chronic gastritis associated with H. pylori showed an eradication rate of 39%[84].

Probiotic monotherapy can be considered as an alternative therapy in cases of polyvalent allergic reactions to antibiotics, as the eradication rate of this treatment is significantly lower compared to standard regimens. Additionally, probiotic monotherapy may be preferred in pediatric practice for children under 10 years of age. Among the different monotherapy options, the most promising results were observed with multi-strain probiotics (32.5%), S. boulardii (28%), a complex of C. butyricum and B. coagulans (26%), and L. reuteri (14.2%). Our data on the efficacy of E. faecium L3 showed a 39% eradication rate, but further multicenter clinical trials are needed to confirm these findings.

WHAT ARE AUTOPROBIOTICS?

The benefits of probiotics arise from the interaction of probiotic strains or strain compositions with the host microbiota. However, probiotic therapy has certain limitations, including the risk of strain colonization failure and the need for a prolonged administration course (1 month or more). Additionally, selecting the most appropriate probiotic for a specific patient from the vast range of options available today remains unclear.

A novel and innovative approach to enhance the effectiveness of correcting gut microbiota disorders and personalized therapy is the development of autoprobiotics (the term proposed by the authors who obtained a patent for the invention)[85].

Autoprobiotics are strains of indigenous microbiota that are isolated from a specific individual and intended to restore his/her gastrointestinal tract microecology. Autoprobiotics can be prepared by culturing individual clones of indigenous bacteria (such as bifidobacteria, lactobacilli, or enterococci) on nutrient cultural media outside the body, or by culturing a complex of indigenous bacteria under anaerobic conditions[86]. Initially, the selection of autoprobiotic strains involved the addition of blood serum[87], but later it was replaced by molecular genetic testing of the strains of interest[88,89].

The advantages of autoprobiotics are: (1) Individual composition: Each autoprobiotic is unique and tailored to the specific beneficial bacteria isolated from an individual's biomaterial; (2) High survival rate: Since the body has been exposed to its own bacteria throughout life, the "survival rate" of auto-probiotics tends to be close to 100%; (3) Safety: Autoprobiotics consist of two main components - the actual indigenous bacteria and special nutrients to support bacterial viability. The body develops immunological tolerance towards the indigenous bacteria included in the autoprobiotic from early years, and they do not enter into conflict with other resident representatives of the human microbiota; and (4) Extended duration in the gut: Compared to probiotics, autoprobiotics have a longer duration in the gut, allowing for shorter treatment courses (as short as 10 d).

Experimental studies utilizing autoprobiotics have demonstrated that in rats with antibiotic-associated dysbiosis, the administration of different indigenous strains of bacteria (such as bifidobacteria, enterococci, or a bacterial mixture) resulted in a rapid restoration of the microbiota compared to untreated animals[86,90]. Several clinical studies have already shown the effectiveness of autoprobiotics based on indigenous strains of Lactobacillus spp. in restoring and stabilizing the levels of key representatives of the normal intestinal microbiota (such as Bifidobacterium spp., Lactobacillus spp., and E. coli) in dysbiotic disorders caused by antibiotic usage[91-93], as well as in infection and inflammatory diseases[86,90,94]. The efficacy of monotherapy using autoprobiotics based on indigenous non-pathogenic enterococci has been demonstrated in the treatment of chronic gastritis associated with H. pylori: The eradication rate was 80%, and there was 100% relief of symptoms after a 20-d autoprobiotic treatment[95].

The high efficacy of autoprobiotics in H. pylori eradication can be attributed to their personalized effect on the host gastrointestinal microbiota. It can be hypothesized that the use of indigenous microorganisms holds greater potential compared to the administration of commercial probiotics.

DISCUSSION

The addition of probiotics to standard triple or quadruple therapy has shown significant improvement in H. pylori eradication efficacy and reduction in adverse reactions associated with anti-H. pylori antibiotics, such as diarrhea and nausea. However, some studies have indicated that probiotics do not have a significant positive influence on the eradication rate and/or the frequency of adverse reactions, which may depend on the specific microbial strain(s) included in the product. Therefore, further randomized multicenter studies are necessary to investigate the effects of probiotics against H. pylori, focusing on strains with specific anti-H. pylori activity.

Probiotic monotherapy has demonstrated successful eradication rates of up to 39% for H. pylori, which are significantly higher than the percentages of spontaneous eradication (3%-5%). Probiotic monotherapy can be considered as an alternative method of treating H. pylori-associated diseases, particularly when standard anti-H. pylori therapy with antibiotics is not effective.

There are several interesting and controversial points to consider regarding the use of probiotics as an additional treatment for H. pylori infection: Probiotics can be administered for a longer duration: Unlike aggressive eradication therapy, which lasts 10-14 d, the duration of probiotic therapy is not strictly regulated. It is important to determine the optimal duration for each probiotic strain to achieve the best therapeutic outcomes and predict clinical effects.

Probiotics are generally safer than antibiotics but may still have side effects. Further studies are needed to identify possible side effects associated with different probiotic strains, in order to choose the safest and most effective options.

Possible approaches to prescribing probiotic therapy for patients with H. pylori-associated diseases include: Pre-eradication probiotic therapy: Prescribing probiotics 3-4 wk before eradication therapy to realize the immunomodulatory effects and enhance the predictability of positive eradication outcomes; Co-eradication probiotic therapy: Prescribing probiotics simultaneously with eradication therapy (10-14 d) to increase eradication effectiveness and reduce the risk of side effects; Post-eradication probiotic therapy: Prescribed for a period of 3-4 wk after eradication to restore the gut microbiota and reduce the risk of H. pylori reinvention (recolonization).

Probiotic monotherapy may be prescribed to patients with a history of allergic reactions to antibiotics included in eradication regimens, or if the patient categorically refuses to take antibiotics, or for asymptomatic young children. In such cases, probiotics should be administered for a minimum of 1 month. However, it is important to note that this type of therapy exhibits lower efficacy compared to standard regimens, which significantly limits its application.

Autoprobiotics represent a novel type of probiotics with promising results in terms of anti-H. pylori efficacy. However, randomized placebo-controlled multicenter studies are necessary to confirm their efficacy and safety.

These considerations highlight the potential benefits and challenges associated with probiotic therapy in the context of H. pylori infection and suggest various strategies for optimizing its use.

CONCLUSION

The incorporation of probiotics into complex eradication therapy holds promise for optimizing the treatment of H. pylori infection. Probiotic strains, through their correction of gastric and gut microbiota, immunomodulatory effects, and direct antagonistic activity against H. pylori (via bacteriocins and other factors such as bacterial synthesized acids and hydrogen peroxide), can improve eradication rates, reduce the frequency and severity of side effects, and enhance patient compliance and treatment outcomes (Figure 1).

While probiotics alone cannot surpass antibiotics in the eradication of H. pylori, they play an important role as an additional component to triple or quadruple therapy, particularly in cases of antibiotic resistance. Therefore, it is recommended to include probiotics as adjunctive medicines in anti-H. pylori regimens. Probiotic or autoprobiotic monotherapy can be used as an alternative treatment method for individuals with allergic reactions to antibiotics. Furthermore, identifying the optimal probiotic/autoprobiotic strain or combination of strains for each patient is crucial for achieving the best clinical results and eradication rates. This represents an important objective for future investigations.